Search Results - "Adeni, Anika E."

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd by Haikala, Heidi M, Lopez, Timothy, Köhler, Jens, Eser, Pinar O, Xu, Man, Zeng, Qing, Teceno, Tyler J, Ngo, Kenneth, Zhao, Yutong, Ivanova, Elena V, Bertram, Arrien A, Leeper, Brittaney A, Chambers, Emily S, Adeni, Anika E, Taus, Luke J, Kuraguchi, Mari, Kirschmeier, Paul T, Yu, Channing, Shiose, Yoshinobu, Kamai, Yasuki, Qiu, Yang, Paweletz, Cloud P, Gokhale, Prafulla C, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC)…”
Get full text

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations by Ogino, Atsuko, Choi, Jihyun, Lin, Mika, Wilkens, Margaret K., Calles, Antonio, Xu, Man, Adeni, Anika E., Chambers, Emily S., Capelletti, Marzia, Butaney, Mohit, Gray, Nathanael S., Gokhale, Prafulla C., Palakurthi, Sangeetha, Kirschmeier, Paul, Oxnard, Geoffrey R., Sholl, Lynette M., Jänne, Pasi A.

“…Small‐cell lung cancer (SCLC) occurs infrequently in never/former light smokers. We sought to study this rare clinical subset through next‐generation…”
Get full text

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients by Nishino, Mizuki, Ramaiya, Nikhil H., Chambers, Emily S., Adeni, Anika E., Hatabu, Hiroto, Jänne, Pasi A., Hodi, F. Stephen, Awad, Mark M.

“…BackgroundTumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with…”
Get full text

Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome by Nishino, Mizuki, Dahlberg, Suzanne E, Adeni, Anika E, Lydon, Christine A, Hatabu, Hiroto, Jänne, Pasi A, Hodi, F Stephen, Awad, Mark M

“…We evaluated tumor burden dynamics in patients with advanced non-small cell lung cancer (NSCLC) treated with commercial PD-1 inhibitors to identify imaging…”
Get full text

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer by Ostios-Garcia, Lorena, Faig, Jennifer, Leonardi, Giulia C, Adeni, Anika E, Subegdjo, Safiya J, Lydon, Christine A, Rangachari, Deepa, Huberman, Mark S, Sehgal, Kartik, Shea, Meghan, VanderLaan, Paul A, Cheng, Matthew P, Marty, Francisco M, Hammond, Sarah P, Costa, Daniel B, Awad, Mark M

“…Despite widespread administration of programmed death receptor 1 (PD-1) pathway inhibitors among individuals with NSCLC, little is known about the safety and…”
Get more information

Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor by Alessandrino, Francesco, Sahu, Sonia, Nishino, Mizuki, Adeni, Anika E., Tirumani, Sree Harsha, Shinagare, Atul B., Awad, Mark M.

“…Purpose To investigate the frequency and imaging features of radiographically evident abdominal immune-related adverse events (irAEs) in patients with…”
Get full text

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer by Awad, Mark M, Mastini, Cristina, Blasco, Rafael B, Mologni, Luca, Voena, Claudia, Mussolin, Lara, Mach, Stacy L, Adeni, Anika E, Lydon, Christine A, Sholl, Lynette M, Jänne, Pasi A, Chiarle, Roberto

“…The anaplastic lymphoma kinase (ALK) is recognized by the immune system as a tumor antigen, and preclinical evidence suggests that ALK-rearranged NSCLCs can…”
Get full text

Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC) by Ricciuti, Biagio, Champagne, Christine, Jones, Greg, Lazarus, Tadd Scott, Adeni, Anika E., Cheng, Michael L., Oxnard, Geoffrey R., Awad, Mark M.

“…Abstract only 3518 Background: ctDNA shedding into plasma can be prognostic in lung cancer, and changes in plasma ctDNA levels correlate with response to…”
Get full text

Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors by Jimenez Aguilar, Elizabeth, Rizvi, Hira, Kravets, Sasha, Lydon, Christine A., Adeni, Anika E., Subegdjo, Safiya, Hellmann, Matthew David, Awad, Mark M.

“…Abstract only…”
Get full text

Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting by Nishino, Mizuki, Dahlberg, Suzanne Eleanor, Adeni, Anika E, Lydon, Christine A., Hatabu, Hiroto, Janne, Pasi A., Hodi, F. Stephen, Awad, Mark M.

“…Abstract only 9087 Background: PD-1 inhibitors have shown promising activity in advanced NSCLC, with increasing clinical use. We evaluated tumor burden…”
Get full text

Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90 by Jimenez Aguilar, Elizabeth, Ricciuti, Biagio, Gainor, Justin F., Nishino, Mizuki, Adeni, Anika E., Subegdjo, Safiya, Khosrowjerdi, Sara, Peterson, Rachel, Digumarthy, Subba, Liu, Corinne, Sauter, Jennifer L., Rizvi, Hira, Arbour, Kathryn Cecilia, Carter, Brett W., Heymach, John, Altan, Mehmet, Hellmann, Matthew David, Awad, Mark M.

“…Abstract only 9111 Background: In non-small cell lung cancers with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of ≥50%, first-line…”
Get full text